Want to see UNCY full AI Analyst Report?
Top Page
Unicycive Therapeutics
(NASDAQ:UNCY)
Select Model
Select Model
Rating:42Neutral
Price Target:
$4.50
▼(-35.90% Downside)
Action:Reiterated
Date:07/01/26
The score is primarily constrained by weak financial performance (no revenue, sustained losses, and material cash burn) and a clearly negative technical trend (price below all major moving averages). A low-debt balance sheet and improving equity provide some support, but valuation metrics are not meaningfully positive given the current loss-making profile and lack of dividend data.
Positive Factors
Conservative balance sheet
Very low leverage and materially improved equity reduce insolvency risk and increase strategic optionality. A conservatively levered balance sheet supports remediation or partner negotiations, and provides a buffer to fund near-term regulatory activities or development milestones over the next several months.
Negative Factors
No revenue / sustained losses
The company remains pre-revenue and materially loss-making, indicating no internal cash generation from products. Persistent net losses limit reinvestment capacity, lengthen time to self-sufficiency, and make the business dependent on external funding sources for program progression.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and materially improved equity reduce insolvency risk and increase strategic optionality. A conservatively levered balance sheet supports remediation or partner negotiations, and provides a buffer to fund near-term regulatory activities or development milestones over the next several months.
Read all positive factors
Unicycive Therapeutics (UNCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$125.22M
Dividend YieldN/A
Average Volume (3M)814.92K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue GrowthN/A
EPS Growth-36.64%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.05
Shares Outstanding26,700,027
10 Day Avg. Volume1,053,209
30 Day Avg. Volume814,925
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)30.36
Price to Sales (P/S)0.00
P/FCF Ratio-29.25
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-329.75
Enterprise Value/Ebitda-2.93
Forecast
1Y Price Target
$37.83Price Target Upside438.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.43
Revenue Forecast (FY)$17.83M
Unicycive Therapeutics Business Overview & Revenue Model
Company Description
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patien...
How the Company Makes Money
Unicycive Therapeutics has historically not generated material recurring revenue from product sales because its lead programs have been in development rather than commercialized. As a result, the company’s cash inflows have primarily come from fin...
Unicycive Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 675.00K | 951.00K | 0.00 |
| Gross Profit | -349.00K | -572.00K | 0.00 | 675.00K | 951.00K | 0.00 |
| EBITDA | -39.25M | -25.91M | -36.23M | -30.18M | -17.89M | -9.38M |
| Net Income | -39.95M | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M |
Balance Sheet | ||||||
| Total Assets | 64.41M | 49.13M | 31.67M | 14.19M | 2.82M | 18.74M |
| Cash, Cash Equivalents and Short-Term Investments | 54.59M | 41.27M | 26.14M | 9.70M | 455.00K | 16.58M |
| Total Debt | 941.00K | 199.00K | 773.00K | 811.00K | 201.00K | 335.00K |
| Total Liabilities | 26.70M | 18.94M | 24.24M | 18.00M | 3.28M | 2.26M |
| Stockholders Equity | 37.70M | 30.20M | 7.43M | -3.81M | -466.00K | 16.48M |
Cash Flow | ||||||
| Free Cash Flow | -28.67M | -31.34M | -28.65M | -18.30M | -15.65M | -5.80M |
| Operating Cash Flow | -28.66M | -31.32M | -28.57M | -18.28M | -15.65M | -5.77M |
| Investing Cash Flow | -17.23M | -12.10M | -72.00K | -12.00K | -2.00K | -29.00K |
| Financing Cash Flow | 63.49M | 46.47M | 45.09M | 27.54M | -471.00K | 22.38M |
Unicycive Therapeutics Technical Analysis
Negative
7.02
Price Trends
7.52
Negative
7.10
Negative
6.25
Negative
Market Momentum
-0.18
Positive
31.49
Neutral
31.96
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Negative. The current price of 7.02 is below the 20-day moving average (MA) of 7.25, below the 50-day MA of 7.52, and above the 200-day MA of 6.25, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 31.49 is Neutral, neither overbought nor oversold. The STOCH value of 31.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNCY.
Unicycive Therapeutics Risk Analysis
Unicycive Therapeutics disclosed 56 risk factors in its most recent earnings report. Unicycive Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Unicycive Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $101.65M | 0.79 | 163.88% | ― | 14.50% | ― | |
53 Neutral | $202.32M | -8.41 | -61.43% | ― | -100.00% | 18.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $104.57M | -0.78 | -225.59% | ― | -9.79% | 82.00% | |
43 Neutral | $15.07M | -0.30 | -226.10% | ― | ― | 71.62% | |
42 Neutral | $125.22M | -2.26 | -131.18% | ― | ― | -36.64% |
* Healthcare Sector Average
UNCY
Unicycive Therapeutics
5.28
0.64
13.79%
CVM
Cel-Sci
1.05
-1.47
-58.33%
FBIO
Fortress Biotech
3.09
1.26
68.85%
CBUS
Cibus
1.42
-0.09
-5.96%
EQ
Equillium
3.04
2.72
855.97%
Unicycive Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Unicycive Expands At-The-Market Equity Offering Program
Neutral
Jun 5, 2026
Unicycive Therapeutics, Inc. expanded its existing at-the-market equity program originally established in November 2024 with Guggenheim Securities, LLC, increasing the maximum aggregate offering size of its common stock from $100 million to $150 m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.